PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
Titel:
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
Auteur:
Evrard, Camille Louvet, Christophe Hajbi, Farid EL Fiore, Frédéric DI Malicot, Karine LE Aparicio, Thomas Bouché, Olivier Laurent-Puig, Pierre Bibeau, Frédéric Lecomte, Thierry Lièvre, Astrid Guimbaud, Rosine Kim, Stefano Zaanan, Aziz Sokol, Harry Chibaudel, Benoist Desrame, Jérome Pierre, Sabrina Gonzalez, Daniel Lepage, Come Tougeron, David